On January 2, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will be webcasting its corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA (Press release, Jazz Pharmaceuticals, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324485 [SID1234522819]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on Monday, January 8, 2018 at 9:30 a.m. PST / 5:30 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

On January 2, 2018 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported that it will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, Jan. 8, 2018, in San Francisco (Press release, Neurocrine Biosciences, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324471 [SID1234522820]). Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website at View Source A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month

On January 2, 2018 pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, reported that Nancy Lurker, President and Chief Executive Officer, will present at the Annual Biotech Showcase conference on Monday, January 8, 2018 at 3:00 p.m. PT in San Francisco, CA (Press release, pSivida, JAN 2, 2018, View Source [SID1234522821]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio and/or webcast and subsequent archived replay of pSivida’s presentations may be accessed via the Investors section of the Company’s website under "Resources – Events & Presentations" at www.psivida.com. The replay will be available for 90 days after the event.

On January 2, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update for the Company, and host investor meetings at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Supernus, JAN 2, 2018, View Source [SID1234522822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, January 10, 2018
Time: 12:00 p.m. PT / 3:00 p.m. ET
Place: Westin St. Francis Hotel, San Francisco, CA

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of this webcast will be available for 60 days subsequent to the Company’s presentation.

On January 2, 2018 H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using data science and precision chemistry product engine, reported that Markus Warmuth, M.D., President and CEO of H3 Biomedicine, will present an overview of the company and its 2018 goals at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco (Press release, H3 Biomedicine, JAN 2, 2018, View Source [SID1234522809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Warmuth is expected to provide details about the company’s data science and precision chemistry product engine and its clinical pipeline of three differentiated, internally-generated cancer therapies, including:

H3B-8800, an oral, potent and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1) that is being developed by H3 Biomedicine as an anticancer therapeutic agent.
H3B-6527, a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC).
H3B-6545, an orally bioavailable, potent and selective small molecule modulator of wild-type and mutant Estrogen Receptor (ERα).
For more information about H3 Biomedicine’s pipeline, click here.